
    
      This is a Phase 1, open-label, first-in-human (FIH), single-ascending dose (SAD) study
      consisting of approximately 4 cohorts. The total number of patients will be at least 3 per
      cohort plus 3 additional patients in the maximum tolerated dose (MTD) cohort. UBX1325 will be
      administered intravitreally and all patients will be followed for approximately 6 months.
    
  